Long-term follow-up after autologous skeletal myoblast transplantation in ischaemic heart disease

Brickwedel, J.; Gulbins, H; Reichenspurner, Hermann

doi:10.1093/icvts/ivt434

Cited by 35 publications

(33 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[42][43][44] For dichotomous variables, count data were summed across groups and for continuous variables, the mean and standard deviation of the combined group was calculated from the mean and standard deviations of each subgroup.…”

Section: Discussionmentioning

confidence: 99%

Meta-Analysis of Cell Therapy Trials for Patients With Heart Failure

Fisher

Dorée

Mathur

et al. 2015

Circulation Research

188

158

View full text Add to dashboard Cite

Rationale: Cell-based therapies are a promising intervention for the treatment of heart failure (HF) secondary to ischemic and nonischemic cardiomyopathy. However, the clinical efficacy of such new treatment requires further evaluation. Objective: To assess available clinical evidence on the safety and efficacy of cell-based therapies for HF. Methods and Results: Electronic databases (CENTRAL, DARE, NHSEED & HTA, PubMed, MEDLINE, EMBASE, CINAHL, LILACS, KoreaMed, PakMediNet, IndMed, and the Transfusion Evidence Library) were searched for relevant randomized controlled trials to June 2014. Trials of participants with HF and where the administration of any dose of autologous cells by any delivery route was compared with no intervention or placebo were eligible for inclusion. Primary outcomes were defined as mortality and rehospitalization as a result of HF. Secondary outcomes included performance status, quality of life, incidence of arrhythmias, brain natriuretic peptide levels, left ventricular ejection fraction, myocardial perfusion, and adverse events. Thirty-one independent trials (1521 participants) were included. The treatment significantly reduced the risk of mortality and rehospitalization caused by HF. There was a significant improvement in favor of stem cell treatment in performance status and exercise capacity, left ventricular ejection fraction, and quality of life. The treatment was also associated with a reduction of brain natriuretic peptide levels and no increase in the incidence of arrhythmias. However, there was considerable risk of performance, selection, and reporting bias among the included trials. Conclusions: This study shows evidence that autologous cell therapy may be beneficial for patients having HF, but further evidence is required.

show abstract

Section: Discussionmentioning

confidence: 99%

Meta-Analysis of Cell Therapy Trials for Patients With Heart Failure

Fisher

Dorée

Mathur

et al. 2015

Circulation Research

188

158

View full text Add to dashboard Cite

show abstract

“…The results in small size studies were somewhat promising. 18,[76][77][78] However, despite the encouraging results in small and observational studies, the overall results of larger clinical studies have not been impressive but rather null. Given the risk of cardiac arrhythmias associated with injection of myoblasts and the availability of other cell types, autologous skeletal myoblasts are not considered the prime cell type for heart failure therapy.…”

Section: Clinical Trials In Human Patientsmentioning

confidence: 99%

Recent Developments in Cardiovascular Stem Cells

Madonna

Ferdinándy

Caterina

et al. 2014

Circulation Research

View full text Add to dashboard Cite

45Human embryonic stem cells have been shown to differentiate to beating cardiomyocytes, SA nodal-like cells and mesodermal Recent Developments in Cardiovascular Research:The goal of "Recent Developments" is to provide a concise but comprehensive overview of new advances in cardiovascular research, which we hope will keep our readers abreast of recent scientific discoveries and facilitate discussion, interpretation, and integration of the findings. This will enable readers who are not experts in a particular field to grasp the significance and effect of work performed in other fields. It is our hope and expectation that these "Recent Development" articles will help readers to gain a broader awareness and a deeper understanding of the status of research across the vast landscape of cardiovascular research-The Editors. 50 Moreover, the use of induced pluripotent stem cell-derived cardiac myocytes for cardiac repair is hampered by their immature phenotype and the presence of epigenetic and genetic changes.24,51,52 Resident and bone marrow cells and cortical bone-derived cells are considered as potential sources for differentiation to cardiac myocytes but lacking compelling evidence for cardiac myogenesis and perhaps exerting their salutary biological effects through paracrine mechanisms. 19,29,[53][54][55][56][57][58] Equally exciting and challenging are the discovery and characterization of other CPCs that could give raise to various cardiac cells types, including smooth muscle cells, endothelial cells, and fibroblasts. [59][60][61][62][63] An important problem to overcome is the multiple comorbidities and their comedications of ischemic heart disease patients with heart failure that may affect cytoprotective signaling triggered by the different stem cell, as well as survival and differentiation properties of such stem cells in the injured tissue. [64][65][66] Clearly, the rapid face of discoveries is dazzling and a complete coverage of the recent developments in cardiovascular stem cells would be beyond the scope of this article. We regret that many valuable works were not covered in part or at all included in the present overview on Recent Developments. Clinical Trials In Human PatientsThe ClinicalTrials.gov lists >1000 clinical trials including >600 studies in the United States alone that tests effects of various stem cells in human patients (http://www.clinicaltrials. gov/). The list includes 71 including 38 active clinical trials in patients with heart failure using various stem cells, such as adipose-derived, mesenchymal, human embryonic, autologous CD133 + and CD34 + stem cells among the others.18,67-74Autologous skeletal myoblasts were probably the first cell type used to regenerate functional myocardium. It was tested initially in a rabbit model of myocardial cryoinjury, which showed incorporation of the injected myoblasts and improved myocardial performance. 75 Subsequent observational studies were followed by randomized clinical trials in human patients with heart failure injected with autologous skele...

show abstract

“…Currently, the biggest obstacle regarding the use of SkMCs in clinical treatment is that the differentiated SkMCs do not express gap junction proteins, which can potentially induce arrhythmias in recipient [27] . However, this consequence was not proven in the first randomized placebo-controlled study and long-term follow up of the MI patients after skeletal myoblast transplantation [13,28] . Further large animal model studies and clinical trials of SkMCs therapy may pay more attention to the effect of this therapy on the physiological function of the heart receiving the cells.…”

Section: Skeletal Muscle Stem Cellsmentioning

confidence: 99%

“…Animal experiments showed that stem cell transplantation can contribute to the regeneration of cardiomyocyte and improve cardiac function [11,12] . Some of the stem cell types are being applied in clinical trials to prove it an acceptable and applicable treatment in human [13,14] . There are two main types of stem cells used in myocardium regeneration, pluripotent stem cells including embryonic stem cells (ESC) and induced pluripotent stem (iPS), and adult stem cells including mesenchymal stem cells, skeletal muscle myoblast cardiac stem cells (CSC) and bone marrow cells (BMC) (Figure 1).…”

Section: New Strategiesmentioning

confidence: 99%

New Strategies for Myocardial Infarction Treatment

Peng

Zhou

2017

Journal of Cardiology and Therapy

View full text Add to dashboard Cite

At present, the treatments of myocardial infarction mainly focus on the recanalization of the occluded coronary artery to restore perfusion and prevent myocardial necrosis. To do this, commonly used methods include drug therapy, thrombolytic therapy, percutaneous coronary intervention (PCI), and coronary artery bypass graft (CABG) surgery. Drug therapiesTraditional drug therapies include angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs), aldosterone receptor antagonists, β-receptor blockers, and so on [1][2][3] . The main purpose of these treatments is the prevention of left ventricular remodeling. Thrombolytic therapy ABSTRACTMyocardial infarction is due to lasting and serious myocardial ischemia that leads to myocardial necrosis and cardiac remodeling, and can consequently result in heart failure. Traditional treatment for myocardial infarction includes drug therapy, thrombolytic therapy, percutaneous coronary intervention (PCI), and coronary artery bypass graft (CABG) surgery. Although these treatments can to some extent relieve the symptom of myocardial ischemia, they fail to repair the necrotic heart tissues. Myocardial regeneration is undoubtedly the best solution to the clinical problems of myocardial infarction treatment. The review briefly illustrated the pros and cons of the traditional treatments of myocardial infarction, and focused on the application of new strategies for myocardial infarction treatment using myocardial regeneration.

show abstract

Long-term follow-up after autologous skeletal myoblast transplantation in ischaemic heart disease

Cited by 35 publications

References 21 publications

Meta-Analysis of Cell Therapy Trials for Patients With Heart Failure

Meta-Analysis of Cell Therapy Trials for Patients With Heart Failure

Recent Developments in Cardiovascular Stem Cells

New Strategies for Myocardial Infarction Treatment

Contact Info

Product

Resources

About